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Abstract
The DNA double strand break repair gene TOPBP1 has been suggested as a breast cancer susceptibility gene and a
missense variant Arg309Cys was observed at elevated frequency in familial breast cancer cases compared to
healthy controls from Finland. We found the Arg309Cys allele at a 13% carrier frequency in a hospital-based series
of 1064 German breast cancer patients and at a 14% carrier frequency in 1014 population controls (OR 0.89, 95%CI
0.69-1.15; p = 0.4). Arg309Cys carriers were not enriched among patients with a family history of breast cancer (OR
= 0.87, 95%CI 0.53-1.43, p = 0.6) and were slightly underrepresented in patients with bilateral disease (OR = 0.49,
95%CI = 0.24-0.99; p = 0.047). In the latter group, the mean age at diagnosis was 62 years in carriers and 54 years
in non-carriers (p = 0.004). We conclude that there is no evidence for the TOPBP1*Arg309Cys variant to confer an
increased risk for breast cancer in the German population.
Findings
Only a small proportion of breast cancer cases can be
attributed to mutations in high-penetrance genes such
as BRCA1 or BRCA2, and much of the remaining cases
are attributed to more common gene variants with
lower penetrance [1,2]. As many of the hitherto known
susceptibility factors have been implicated in the cellular
responses to DNA double-strand breaks and replication
stress, there is considerable interest in genetic variants
of additional proteins involved in these pathways [2].
TOPBP1 encodes a protein that shares homology to
BRCA1, is aberrantly expressed in breast carcinomas
and has a critical role in DNA damage and replication
checkpoint pathways [3-7]. TOPBP1 encodes a 1522
amino acid BRCT domain protein that interacts with
DNA topoisomerase IIb a n di si n v o l v e di nA T M / A T R -
mediated DNA damage and replication checkpoint path-
ways [3-6]. Reduced or aberrantly localized TopBP1
expression has been observed in a significant proportion
of breast cancer specimens [7]. Functional TOPBP1
variants therefore represent plausible candidate breast
cancer susceptibility alleles. A recent sequencing and
case-control association study has assessed the role of
germ-line variants in Finnish breast and ovarian cancer
patients [8]. The novel Arg309Cys substitution was
observed at significantly higher frequency in 125 familial
breast and/or ovarian cancer patients compared to 697
healthy controls (15.2% versus 7.0%; P = 0.002), and a
2.4-fold increase in risk was suggested [8]. We aimed to
corroborate this finding in a hospital-based series of
1064 German breast cancer patients and 1014 popula-
tion controls.
Our German study population consisted of a hospital-
based series of 1012 unselected breast cancer patients
who were treated at the Department of Radiation
Oncology at Hannover Medical School from 1996-1999
and an additional small series of 52 patients with bilat-
eral breast cancer collected later from the same hospital.
Median age at onset of breast cancer was 57 years in
this patient group, and 144 patients (13.5%) reported at
least one first-degree relative with breast cancer. The
series had been used previously to determine the fre-
quency of mutations in the BRCA1, ATM, NBS1 and
CHEK2 g e n e sa sw e l la st oc h a r a c t e r i z em o r ec o m m o n
polymorphisms studied by the Breast Cancer Associa-
tion Consortium. The population controls were 1014
anonymous female German volunteers who had been
ascertained between August and December 2005 at
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Written informed consent had been obtained from all
patients, and the study was approved by the local Ethics
Commission.
Genomic DNA was isolated from peripheral white
blood cells using a routine protocol employing protei-
nase K digestion and phenol-chloroform extraction. A
region spanning the exon 8 was amplified by PCR with
the primers 5’-AGATTTCAGTAAACACCCCTG-3’
(forward) and 5’-GGTCTTCAAAGTCAGGCTAG-3’
(reverse) using HotStart Taq DNA Polymerase (Qiagen)
and 35 cycles of 1 min denaturation at 94°C, 1 min
annealing at 60°C and 1 min extension at 72°C. 168
samples were initially evaluated by restriction-enzyme
based analysis to identify heterozygous and homozygous
carriers. For this purpose, PCR products were incubated
with Tat I (Fermentas) and analysed on a 2% agarose gel.
We further established a 5’-nuclease assay for the discri-
mination of the Arg and Cys alleles using specific FAM-
or VIC-labelled MGB probes (Applied Biosystems). The
probe sequences were 5’-VIC- TGAAAGAGTACGACC-
TACA- MGB- 3’ and 5’-FAM- TGAAAGAGTACAACC-
TACA- MGB- 3’, respectively. 60 PCR cycles with an
annealing step at 60°C were performed in 96-well-plates
o naF A S T7 5 0 0S e q u e n c eD e t e c t i o nS y s t e m( A p p l i e d
Biosystems), and genotypes were determined from the
fluorescence emission in each well using the FAST 7500
Sequence Detection System software. The call rate was
98.8% in the breast cancer samples and 99.9% in the con-
trol series.
To further validate the results of mutation screening,
all homozygotes and selected heterozygous samples
were confirmed by direct sequencing using a BigDye
Terminator protocol and capillary gel electrophoresis on
an Avant 3100 Sequence Analyser (Applied Biosystems).
Results from direct sequencing, restriction enzyme ana-
lysis and from the 5’nuclease assay were concordant in
all samples.
Genotype distributions were compared between cases
and controls, or between different patient subgroups,
and odds ratios were determined under dominant, co-
dominant and recessive models using the SNP & Varia-
tion Suite 7.0 software (Golden Helix Inc.). Results were
considered non-significant for p-values > 0.05 (2 df).
Ages at diagnosis were compar e du s i n gaT - t e s t( M i n i -
tab 15) and a median test (Statistix 7.0).
We confirmed the Arg309Cys missense substitution in
an initial sample by restriction enzyme analysis and
direct sequencing, and then employed a 5’-nuclease
assay for the discrimination of the Arg and Cys alleles
in genomic DNA samples from all the HaBCS case-con-
trol series (Figure 1). Variant genotype data were
Figure 1 Detection and screening of the TOPBP1*Arg309Cys
substitution by (a) direct sequencing, (b) restriction enzyme
analysis, and (c) 5’-nuclease allelic discrimination assay.a )
Direct sequencing of the sense strand of TOPBP1 exon 8. From top
to bottom: Homozygous genotype Arg/Arg, heterozygosity Arg/Cys,
homozygous genotype Cys/Cys. The position of the mutation is
marked by an asterisk. b) Restriction enzyme analysis after
incubation with Tat I and 2% agarose gel electrophoresis. Lanes
from left to right: common homozygote (Arg/Arg, 1-1),
heterozygous sample (Arg/Cys, 1-2), rare homozygote (Cys/Cys, 2-2).
c) 5’-nuclease allelic discrimination assay identifying common
homozygotes (Arg/Arg, red circles), heterozygotes (Arg/Cys, green
triangles), and rare homozygotes (Cys/Cys, blue square). NTC, no
template control.
Table 1 Arg309Cys genotype distribution in German breast cancer cases and controls
TOPBP1 Genotype OR (95% CI) (any Cys vs. Arg/Arg) p
Arg/Arg Arg/Cys Cys/Cys
Population controls (n = 1014) 879 (.87) 130 (.13) 5 (.005)
Breast cancer (n = 1064) 936 (.88) 123 (.12) 5 (.005) 0.89 (0.69-1.15) 0.39
- familial 150 (.88) 19 (.11) 1 (.01) 0.87 (0.53-1.43) 0.56
- bilateral 118 (.93) 9 (.07) 0 0.49 (0.24- 0.99) 0.047
- age < 50 ys 263 (.89) 31 (.10) 2 (.01) 0.82 (0.55-1.22) 0.37
- ductal 606 (.90) 69 (.10) 2 (.003) 0.76 (0.56-1.04) 0.09
- node positive 270 (.88) 36 (.12) 1 (.01) 0.89 (0.61-1.32) 0.63
- ER negative 72 (.87) 10 (.12) 1 (.01) 0.99 (0.51-1.92) 1
Relative distribution of TOPBP1 codon 309 genotypes in cases and controls shown as number of carriers and, in brackets, as relative fraction. Odds ratios are
calculated for carriers of the rare Cys309 allele (with homozygous and heterozygotes combined) versus common homozygotes. P values were calculated using
Fisher’s exact test.
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cancer, and 14 with in situ carcinoma) and 1014 female
population controls. We did not detect significant differ-
ences neither in the allelic nor in the genotypic distribu-
tion of the Arg309Cys variant between the case and
control series under any of the three models applied.
Results obtained under a dominant model, with hetero-
zygous and homozygous carriers combined, are pre-
sented in Table 1. When stratified by clinical
parameters, the most suggestive trend was a slightly
lower frequency of the variant in patients with bilateral
disease compared with controls (OR = 0.49, 95%CI =
0.24-0.99; p = 0.047) (Table 1), contrary to the expected
increase in risk for variant carriers. Furthermore, the
mean age at diagnosis of the first cancer among patients
with bilateral disease was 62.3 years in carriers and 53.8
years in non-carriers (p = 0.004) (Figure 2). Median age
at diagnosis was also higher in the carrier group (p =
0.02). Among patients with bilateral disease, Arg309Cys
carriers were underrepresented among patients with
nodal metastasis compared with non-carriers (p = 0.01).
Carriership also tended to occur at a non-significantly
lower frequency in the major group of ductal invasive
cancers (OR 0.76, 95% CI 0.56-1.04, p = 0.09). No differ-
ences between carriers and non-carriers were observed
in the total series with respect to age at diagnosis, hor-
mone receptor or nodal status.
Our data indicate that the Arg309Cys substitution
occurs at a similar frequency in German individuals as
reported in the previous study [8], indicating that its
distribution is not confined to the Finnish population.
However, we could not confirm the hypothesis that it
constitutes a significant risk factor for breast cancer,
and the upper limit of our 95%CI is not included within
the limits proposed in the Finnish Study (95%CI 1.3-4.2,
Ref. [8]). Our study had some 80% power to detect a
1.4-fold difference, thus minor risks cannot be formally
excluded. An important difference between the study by
Karppinen et al. [8] and ours is that the former focussed
on familial breast cancer whereas we analysed a hospi-
tal-based series unselected for family history. On the
other hand, no trend became apparent when the patient
subgroup with a first-degree family history of breast
cancer in our series was analysed separately. An addi-
tional indicator for a genetic predisposition is bilateral
disease [9]. However, our results showed that the
Arg309Cys variant was rather underrepresented in cases
with bilateral breast cancer compared to healthy con-
trols, and we furthermore observed significant differ-
ences between carriers and non-carriers with respect to
the age at diagnosis which may suggest a protective role
for the Cys allele.
Altogether, we find no general association of the
TOPBP1 Arg309Cys variant with breast cancer risk, and
the direction of the marginally significant association
with bilateral disease in our study is in conflict with the
original data. Our results thus do not support the
increased risk for Arg309Cys, though it cannot be ruled
out that TOPBP1 variants exist which may confer an
increased susceptibility towards breast cancer. In the
initial report, however, the Arg309Cys substitution was
among five different coding variants the only one that
appeared associated with breast cancer. From our
results, there is no evidence to conclude that the
Arg309Cys substitution is a strong cancer susceptibility
allele. Further research may reveal whether any TOPBP1
gene variants can contribute to hereditary breast cancer
risk.
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Figure 2 Mean age at diagnosis of the first primary in patients
with bilateral breast cancer stratified by TOPBP1 codon 309
genotypes. The mean is indicated by a black diamond, and 95%
confidence intervals are shown.
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